MO-I-100 (50 mg/kg, ip, for 5 consecutive days per week for 2 weeks and then administered every other day) reduces tumor growth in an intrahepatic orthotopic xenograft model of HCC[1].
MO-I-1100 (50 mg/kg/day, ip, for 5 days) reduces the activated Notch 1 (cleaved fragment) as well as downstream HES1 and HEY1 gene expression[1].
| Animal Model: | Nude mice with established s.c. tumor xenografts of FOCUS cells[1] |
| Dosage: | 50 mg/kg/day |
| Administration: | Ip, for 5 days |
| Result: | Reduced the activated Notch 1 (cleaved fragment) as well as downstream HES1 and HEY1 gene expression. |
